TrialStem cell research & therapy2023

A novel therapeutic management for diabetes patients with chronic limb-threatening ischemia: comparison of autologous bone marrow mononuclear cells versus allogenic Wharton jelly-derived mesenchymal stem cells.

Martha L Arango-Rodríguez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.